U.S. Markets open in 3 hrs 41 mins

Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%

Zacks Equity Research

Dova Pharmaceuticals, Inc. DOVA was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $14.41 to $17.89 in the past one-month time frame.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
  
Dova Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

Dova Pharmaceuticals, Inc. Price

Dova Pharmaceuticals, Inc. Price

Dova Pharmaceuticals, Inc. price | Dova Pharmaceuticals, Inc. Quote

Investors interested in the Medical - Drugs industry may consider FibroGen, Inc. FGEN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is DOVA going up? Or down? Predict to see what others think: Up or Down

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
Dova Pharmaceuticals, Inc. (DOVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research